A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days

NCT02140320 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma
Healthy Volunteers

Interventions

DRUG: RV1729 single dose
DRUG: RV1729 matching placebo single dose
DRUG: RV1729 14 day repeat dose
DRUG: RV1729 matching placebo 14 day repeat dose
DRUG: RV1729 28 day repeat dose
DRUG: RV1729 matching placebo 28 day repeat dose

Sponsor

Respivert Ltd